Abiopharma

🔍 SOON-SHIONG PATRICK (Director)

Company: ImmunityBio, Inc. (IBRX)

Report Date: 2026-03-31

Detailed Transactions and Holdings:

• Acquired 4,606,596 shares of Common Stock at $5.427 per share (Direct)
  Date: 2026-03-31 | Code: C | equity_swap_involved: 0 | shares_owned_after: 251,018,873.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-31 | Code: H | shares_owned_after: 29,757,911.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-31 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 261,705,814.00 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-31 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 8,383,414.00 | Footnotes: F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-31 | Code: H | nature_of_ownership: See footnte | shares_owned_after: 7,976,159.00 | Footnotes: F4
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-31 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 5,618,326.00 | Footnotes: F5
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-31 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 9,986,920.00 | Footnotes: F6
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-31 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 47,557,934.00 | Footnotes: F7
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-31 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 32,606,985.00 | Footnotes: F8
• Sold 0 shares of Second Amended and Restated Convertible Promissory Note at $5.427 per share (Derivative)
  Date: 2026-03-31 | Code: C | Expires: 2027-12-31 | Exercise: 2024-12-10 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F9, F9, F1

Footnotes:

• F1: Shares held by Nant Capital, LLC, an investment vehicle of the Reporting Person.
• F2: Shares held by Cambridge Equities, LP ("Cambridge Equities"). MP 13 Ventures, LLC ("MP 13 Ventures") is the general partner of Cambridge Equities and may be deemed to have beneficial ownership of the shares held by Cambridge Equities. The Reporting Person is the sole member of MP 13 Ventures and has voting and dispositive power over the shares held by Cambridge Equities.
• F3: Shares held by NantBio, Inc. ("NantBio"). NantWorks, LLC ("NantWorks") is the majority stockholder and an affiliate of NantBio and may be deemed to have beneficial ownership of the shares held by NantBio. The Reporting Person is the chief executive officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the shares held by NantBio.
• F4: Shares held by California Capital Equity, LLC ("CalCap"). The Reporting Person owns all of the equity interests of CalCap and has voting and dispositive power over the shares held by CalCap.
• F5: Shares held by the Chan Soon-Shiong Family Foundation, an exempt corporation organized under the laws of the State of Delaware (the "Foundation"). The Foundation has the sole power to vote and direct the disposition of all shares directly owned by the Foundation, except to the extent it may be deemed to share such power with the Reporting Person by virtue of the Reporting Person's control over the Foundation. The Reporting Person serves as Chairman of the Foundation.
• F6: Shares held by NantWorks. CalCap directly owns all of the equity interests of NantWorks and may be deemed to have beneficial ownership of the securities held by NantWorks. The Reporting Person directly owns all of the equity interests of CalCap and may be deemed to have voting and dispositive power over the securities held by NantWorks.
• F7: Shares held by NantMobile, LLC ("NantMobile"). NantWorks is the majority stockholder and an affiliate of NantMobile and may be deemed to have beneficial ownership of the securities held by NantMobile. The Reporting Person is the Chief Executive Officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the securities held by NantMobile.
• F8: Shares held by NantCancerStemCell, LLC ("NantCancerStemCell"). NantBio is the majority stockholder and an affiliate of NantCancerStemCell and may be deemed to have beneficial ownership of the securities held by NantCancerStemCell. NantWorks is the majority stockholder and an affiliate of NantBio and may be deemed to have beneficial ownership of the securities held by NantBio and its affiliates. The Reporting Person is the Chief Executive Officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the securities held by NantBio and its affiliates.
• F9: Nant Capital has the right at any time after December 10, 2024 and on or before December 31, 2027 to convert all or a portion of the outstanding principal amount of this Second Amended and Restated Promissory Note, as amended January 23, 2026, into fully paid and nonassessable shares of the Issuer's common stock at a price per share equal to $5.427. On March 31, 2026, Nant Capital delivered notice to the Issuer electing to convert outstanding principal in the amount of $25,000,000 into 4,606,596 shares of the Issuer's common stock.
• REMARKS: Founder, Executive Chairman, Global Chief Scientific and Medical Officer